SPYRE THERAPEUTICS, INC. Receivables, Net, Current
SPYRE THERAPEUTICS, INC. (SYRE) had Receivables, Net, Current of $21.50 million as of 2021-03-31, per its 10-Q filed 2021-05-10.
Discontinued › Balance Sheet › Assets › Assets, Current
us-gaap:ReceivablesNetCurrent · last filed 2021-05-10
- 2021-03-31: Receivables, Net, Current $21.50M.
| Period end | Receivables, Net, Current |
|---|---|
| 2021-03-31 | $21.50M 10-Q · filed 2021-05-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |